FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208353443> ?p ?o ?g. }

• W3208353443 endingPage "8541" @default.
• W3208353443 startingPage "8530" @default.
• W3208353443 abstract "Sequential therapy with molecular-targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first-line therapy and to investigate the therapeutic impact of SORA in nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steato hepatitis (NASH)-related HCC.We evaluated 504 HCC patients treated with SORA (Study-1). The times of administration for sorafenib from 2009 to 2015, 2016 to 2017, and 2018 and later were defined as the early-, mid-, and late-term periods, respectively. Among them, 180 HCC patients treated with SORA in addition to MTAs in the mid- and late-term periods were divided into groups based on disease etiology (NAFLD or NASH [n = 37] and viral or alcohol [n = 143]), and outcomes were compared after inverse probability weighting (IPW) (Study-2).Overall survival (OS) of HCC patients who received sequential MTA therapy after first-line SORA was significantly longer. The median survival times (MST) were 12.6 versus 17.6 versus 17.4 months in the early-term group, mid-term group, and the later-time group (early vs. mid, p = 0.014, early vs. later. p = 0.045), respectively. (Study-1). In Study-2, there was no significant differences in OS between the Virus/alcohol group and the NAFLD/NASH group in patients who received sequential therapy (MST was 23.4 and 27.0 months p = 0.173, respectively). The NAFLD or NASH, female sex, albumin-bilirubin (ALBI) grade 2b, and major Vp (Vp3/Vp4) were significant factors for OS treated with SORA.Sequential therapy with SORA as the first-line treatment improved the prognosis of unresectable HCC patients and was effective regardless of HCC etiology." @default.
• W3208353443 created "2021-11-08" @default.
• W3208353443 creator A5002657897 @default.
• W3208353443 creator A5003031164 @default.
• W3208353443 creator A5005361135 @default.
• W3208353443 creator A5006354271 @default.
• W3208353443 creator A5008443307 @default.
• W3208353443 creator A5012339627 @default.
• W3208353443 creator A5012513340 @default.
• W3208353443 creator A5013194037 @default.
• W3208353443 creator A5016855346 @default.
• W3208353443 creator A5019940253 @default.
• W3208353443 creator A5021514669 @default.
• W3208353443 creator A5022848258 @default.
• W3208353443 creator A5033954465 @default.
• W3208353443 creator A5037691579 @default.
• W3208353443 creator A5040485741 @default.
• W3208353443 creator A5042856934 @default.
• W3208353443 creator A5054687903 @default.
• W3208353443 creator A5057606757 @default.
• W3208353443 creator A5057609513 @default.
• W3208353443 creator A5062272413 @default.
• W3208353443 creator A5063172369 @default.
• W3208353443 creator A5074219274 @default.
• W3208353443 creator A5078742949 @default.
• W3208353443 creator A5084839932 @default.
• W3208353443 date "2021-10-24" @default.
• W3208353443 modified "2023-10-16" @default.
• W3208353443 title "First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study" @default.
• W3208353443 cites W1853362908 @default.
• W3208353443 cites W1937746457 @default.
• W3208353443 cites W1971837077 @default.
• W3208353443 cites W2024450952 @default.
• W3208353443 cites W2048613643 @default.
• W3208353443 cites W2079586464 @default.
• W3208353443 cites W2106061083 @default.
• W3208353443 cites W2121960517 @default.
• W3208353443 cites W2148195102 @default.
• W3208353443 cites W2152033211 @default.
• W3208353443 cites W2166108782 @default.
• W3208353443 cites W2560499218 @default.
• W3208353443 cites W2591717879 @default.
• W3208353443 cites W2727497670 @default.
• W3208353443 cites W2759997926 @default.
• W3208353443 cites W2762245091 @default.
• W3208353443 cites W2787358630 @default.
• W3208353443 cites W2795611455 @default.
• W3208353443 cites W2809889937 @default.
• W3208353443 cites W2902313304 @default.
• W3208353443 cites W2904776407 @default.
• W3208353443 cites W2908573150 @default.
• W3208353443 cites W2953618138 @default.
• W3208353443 cites W2981238164 @default.
• W3208353443 cites W3012318418 @default.
• W3208353443 cites W3025022288 @default.
• W3208353443 cites W3040335471 @default.
• W3208353443 cites W3047029710 @default.
• W3208353443 cites W3086672832 @default.
• W3208353443 cites W3133836342 @default.
• W3208353443 cites W3138484572 @default.
• W3208353443 cites W3153247821 @default.
• W3208353443 cites W3208353443 @default.
• W3208353443 cites W4210774372 @default.
• W3208353443 cites W4231821582 @default.
• W3208353443 doi "https://doi.org/10.1002/cam4.4367" @default.
• W3208353443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34693661" @default.
• W3208353443 hasPublicationYear "2021" @default.
• W3208353443 type Work @default.
• W3208353443 sameAs 3208353443 @default.
• W3208353443 citedByCount "11" @default.
• W3208353443 countsByYear W32083534432021 @default.
• W3208353443 countsByYear W32083534432022 @default.
• W3208353443 countsByYear W32083534432023 @default.
• W3208353443 crossrefType "journal-article" @default.
• W3208353443 hasAuthorship W3208353443A5002657897 @default.
• W3208353443 hasAuthorship W3208353443A5003031164 @default.
• W3208353443 hasAuthorship W3208353443A5005361135 @default.
• W3208353443 hasAuthorship W3208353443A5006354271 @default.
• W3208353443 hasAuthorship W3208353443A5008443307 @default.
• W3208353443 hasAuthorship W3208353443A5012339627 @default.
• W3208353443 hasAuthorship W3208353443A5012513340 @default.
• W3208353443 hasAuthorship W3208353443A5013194037 @default.
• W3208353443 hasAuthorship W3208353443A5016855346 @default.
• W3208353443 hasAuthorship W3208353443A5019940253 @default.
• W3208353443 hasAuthorship W3208353443A5021514669 @default.
• W3208353443 hasAuthorship W3208353443A5022848258 @default.
• W3208353443 hasAuthorship W3208353443A5033954465 @default.
• W3208353443 hasAuthorship W3208353443A5037691579 @default.
• W3208353443 hasAuthorship W3208353443A5040485741 @default.
• W3208353443 hasAuthorship W3208353443A5042856934 @default.
• W3208353443 hasAuthorship W3208353443A5054687903 @default.
• W3208353443 hasAuthorship W3208353443A5057606757 @default.
• W3208353443 hasAuthorship W3208353443A5057609513 @default.
• W3208353443 hasAuthorship W3208353443A5062272413 @default.
• W3208353443 hasAuthorship W3208353443A5063172369 @default.
• W3208353443 hasAuthorship W3208353443A5074219274 @default.
• W3208353443 hasAuthorship W3208353443A5078742949 @default.
• W3208353443 hasAuthorship W3208353443A5084839932 @default.

• next